Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256465 | 0.84 | DPP4 (0.33) | ADORA2A | |
| SCHEMBL798556 | 0.81 | GAA (0.32) | CYP3A4TSHRHSD17B10CHRNA7LMNA | |
| SCHEMBL19454166 | 0.81 | CYP3A4 (0.31) | CYP3A4TSHRHSD17B10CHRNA7LMNA | |
| SCHEMBL805074 | 0.77 | CYP2C19 (0.40) | ADORA2ACYP3A4TSHRHSD17B10LMNA | |
| SCHEMBL16219023 | 0.73 | JAK2 (0.39) | — | |
| SCHEMBL12706687 | 0.72 | CYP3A4 (0.32) | CYP3A4TSHRHSD17B10LMNABLM | |
| SCHEMBL6369625 | 0.72 | CYP3A4 (0.53) | ADORA2ACYP3A4TSHRHSD17B10LMNA | |
| SCHEMBL12938135 | 0.71 | CHRNA7 (0.39) | CHRNA7PIK3R1PIK3CA | |
| SCHEMBL172052 | 0.71 | PDCD1 (0.38) | CYP3A4TSHRHSD17B10LMNABLM | |
| SCHEMBL15490062 | 0.70 | DPP4 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291902-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291902-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, PRKG1 | ADORA2A 864/4885CYP3A4 1995/4885TSHR 2096/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | ADORA2A 239/4885CYP3A4 854/4885TSHR 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.